logo
Share SHARE
FONT-SIZE Plus   Neg

Impax Labs. Introduces Oxymorphone Hydrochloride Extended-Release Tablets

Impax Laboratories Inc.(IPXL) said it is commencing shipment of Oxymorphone Hydrochloride Extended-Release Tablets, via. Global Pharmaceuticals, Impax's generics unit.

In June 2010, Impax inked a deal with Endo Pharmaceuticals and Penwest Pharmaceuticals to settle U.S. patent litigation concerning the production and sale of its Oxymorphone Hydrochloride Extended-Release Tablets approved by the U.S. Food and Drug Administration as therapeutically equivalent to the original formulation of OPANA ER. According to the settlement, Endo agreed to grant Impax a license to sell Impax's approved product on January 1, 2013.

Impax also noted that it is actively participating in efforts to support prescriber and patient education of this product through the FDA-approved Risk Evaluation and Mitigation Strategy. Oxymorphone Hydrochloride Extended-Release Tablets are indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
We urge Investors to take advantage of the weakness in the shares of Applied Optoelectronics, Inc. (AAOI), as we believe the stock has at least 15% upside from current levels. The stock is down along with many of the stocks in the Fiber optical component universe with an exposure to China. Nestle SA's shares were gaining around 4 percent in Zurich trading after billionaire activist investor Daniel Loeb's hedge fund Third Point LLC bought a $3.5 billion stake in the Swiss food giant. The acquisition of about 1.25% stake in Nestle would put pressure on the company to find ways to accelerate growth. We believe this stock is well-positioned for at least 15% upside from current $23 levels. The stock featured on our premium product Short-Term Investor on April 25 at an opening price of $19.5, and on June 9 touched an intra-day high of $29.73, returning a gain of 52.4% to investors. It is now at an attractive price point again.
comments powered by Disqus
Follow RTT